First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma.

Abstract

Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immunotherapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option that warrants further clinical evaluation.

• Authors: Neofit J Spasov, Frank Dombrowski, Holger N Lode, Mariya Spasova, Liliya Ivanova, Ivan Mumdjiev, Hassan Burnusuzov, Nikolai Siebert
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 44 Issue 6 Pg. e948-e953 (08 01 2022) ISSN: 1536-3678 [Electronic] United States
• PMID: 35622995 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

Topics

• Consolidation Chemotherapy
• Humans
• Neoplasm Recurrence, Local (drug therapy)
• Sarcoma (drug therapy)
• Sarcoma, Ewing (pathology)
• Soft Tissue Neoplasms (drug therapy)